A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.

Trial Profile

A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Aug 2014

At a glance

  • Drugs Remetinostat (Primary) ; Betamethasone; Calcipotriol
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 10 Jul 2014 A protocol has been amended to change the concentration of drugs: Betamethasone- 0.02%, Calcipotriol - 0.005% and SHP-141C - 0.5%, 1.0% and 2.0%.
    • 10 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 07 Feb 2013 Planned End Date changed from 1 Feb 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top